Correct Answer: D. Imipenem
Imipenem has the highest seizure risk among all carbapenems due to its chemical structure and CNS penetration characteristics. Imipenem is a thienamycin derivative with a 1-β-methyl group that increases its lipophilicity and blood-brain barrier (BBB) penetration compared to other carbapenems. This enhanced CNS accumulation leads to direct neuronal irritation and seizure induction, particularly in patients with renal impairment, meningitis, or pre-existing seizure disorders. The risk is further amplified when renal clearance is compromised, as imipenem accumulates to neurotoxic levels. In Indian clinical practice, imipenem is often reserved for serious infections (nosocomial pneumonia, sepsis) where the benefit outweighs seizure risk, and seizure prophylaxis with cilastatin (a dehydropeptidase inhibitor) is mandatory. Cilastatin not only prevents renal metabolism but also reduces CNS toxicity. Dosage adjustment in renal failure is critical—standard dosing in creatinine clearance <30 mL/min significantly increases seizure incidence. The seizure threshold is further lowered by concurrent use of other CNS-active drugs, electrolyte abnormalities, or high fever.
Why the other options are wrong
A. Meropenem — Meropenem has lower CNS penetration than imipenem due to its 2-β-methyl substitution pattern, which reduces lipophilicity and BBB crossing. It is significantly safer in meningitis and has a lower seizure incidence even in renal failure. Meropenem is the preferred carbapenem in Indian hospitals for CNS infections precisely because of this reduced neurotoxicity profile. B. Doripenem — Doripenem is a newer carbapenem with minimal seizure risk, comparable to meropenem. It has poor CNS penetration and is not associated with increased seizure liability even in renal impairment. Its chemical structure does not promote BBB crossing, making it safer than imipenem in high-risk populations. C. Ertapenem — Ertapenem has very low CNS penetration and is primarily used for community-acquired infections and surgical prophylaxis. It has minimal seizure risk and is often preferred in elderly patients or those with renal compromise. Its longer half-life and lower protein binding do not translate to increased neurotoxicity.
High-Yield Facts
- Imipenem has the highest seizure risk among carbapenems due to enhanced BBB penetration from its 1-β-methyl group.
- Cilastatin (always co-administered with imipenem in India) reduces both renal metabolism and CNS accumulation, lowering seizure risk.
- Seizure risk with imipenem increases dramatically when creatinine clearance <30 mL/min; dosage adjustment is mandatory.
- Meropenem is the preferred carbapenem for meningitis and CNS infections due to lower seizure incidence.
- Imipenem seizures are more common in patients with pre-existing seizure disorder, renal failure, electrolyte abnormalities, or high fever.
Mnemonics
Carbapenem Seizure Risk: IMI-SEIZE IMIpenem = Increased Methyl = Increased seizure risk. The 1-β-methyl group in imipenem makes it lipophilic and BBB-penetrant. Meropenem (2-β-methyl) and others lack this risk. MEDI (Meropenem for meningitis, Doripenem/Ertapenem safer) When choosing carbapenems for CNS infections or high-risk patients: Meropenem is safest, Ertapenem is safe, Doripenem is safe, Imipenem is risky.
NBE Trap
NBE pairs imipenem with "always safe" or "no neurotoxicity" to trap students who memorize that carbapenems are broad-spectrum without learning the critical structural differences. The trap is assuming all carbapenems have identical CNS safety profiles.
Clinical Pearl
In Indian ICUs, when imipenem is used for ventilator-associated pneumonia or sepsis, seizure prophylaxis is standard practice—either through cilastatin co-administration or empiric antiepileptic cover in high-risk patients. A 65-year-old with acute kidney injury receiving imipenem without dose adjustment is at imminent seizure risk and represents a common prescribing error in Indian hospitals.
_Reference: KD Tripathi Pharmacology Ch. 48 (Carbapenems); Harrison Principles of Internal Medicine Ch. 139 (Antimicrobial Agents)_